Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 139 articles:
HTML format



Single Articles


    July 2021
  1. JEANNOT E, Latouche A, Bonneau C, Calmejane MA, et al
    Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer.
    Clin Cancer Res. 2021 Jul 1. pii: 1078-0432.CCR-21-0625.
    PubMed     Abstract available


    June 2021
  2. THOMPSON PA, Huang C, Yang J, Wertheim BC, et al
    Sulindac, a non-selective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0732.
    PubMed     Abstract available


    May 2021
  3. KANDIMALLA R, Wang W, Yu F, Zhou N, et al
    OCaMIR - A noninvasive, diagnostic signature for early stage ovarian cancer: a multi-cohort retrospective and prospective study.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0267.
    PubMed     Abstract available


  4. MIAO YR, Thakkar KN, Qian J, Kariolis MS, et al
    Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
    Clin Cancer Res. 2021 May 19. pii: 1078-0432.CCR-20-0482.
    PubMed     Abstract available


  5. LAUMONT CM, Wouters MCA, Smazynski J, Gierc NS, et al
    Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39, CD103, and PD-1 in ovarian cancer.
    Clin Cancer Res. 2021 May 7. pii: 1078-0432.CCR-20-4394.
    PubMed     Abstract available


    April 2021
  6. FERRALL L, Lin KY, Roden RBS, Hung CF, et al
    Cervical Cancer Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2021 Apr 22. pii: 1078-0432.CCR-20-2833.
    PubMed     Abstract available


  7. FLOBERG JM, Zhang J, Muhammad N, DeWees TA, et al
    Standardized Uptake Value for 18F-Fluorodeoxyglucose is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4450.
    PubMed     Abstract available


    March 2021
  8. THIBODEAUX S, Barnett B, Pandeswara S, Wall S, et al
    Interferon-alpha augments clinical efficacy of regulatory T cell depletion with denileukin diftitox in ovarian cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4594.
    PubMed     Abstract available


  9. CHEN J, Chen C, Zhan Y, Zhou L, et al
    Heterogeneity of interferon-mediated responses and tumor immunogenicity in cervical cancer patients receiving concurrent chemoradiotherapy.
    Clin Cancer Res. 2021 Mar 25. pii: 1078-0432.CCR-20-4521.
    PubMed     Abstract available


  10. DUSKA LR, Filiaci VL, Walker JL, Holman LL, et al
    A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
    Clin Cancer Res. 2021 Mar 25. pii: 1078-0432.CCR-20-4618.
    PubMed     Abstract available


  11. KAZMI F, Nicum S, Roux RL, Spiers L, et al
    A Phase IB open-label, dose-escalation study of NUC1031 in combination with carboplatin for recurrent ovarian cancer.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4403.
    PubMed     Abstract available


  12. EWING A, Meynert A, Churchman M, Grimes G, et al
    Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4068.
    PubMed     Abstract available


    February 2021
  13. MOMENI-BOROUJENI A, Dahoud W, Vanderbilt CM, Chiang S, et al
    Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-4436.
    PubMed     Abstract available


  14. LI N, Bu H, Liu J, Zhu J, et al
    An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3546.
    PubMed     Abstract available


    January 2021
  15. HU Z, Cunnea P, Zhong Z, Lu H, et al
    The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-2782.
    PubMed     Abstract available


    December 2020
  16. PARACCHINI L, Beltrame L, Grassi T, Inglesi A, et al
    Genome-wide copy number alterations in circulating tumor DNA as a novel biomarker in high grade serous ovarian cancer patients.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-3345.
    PubMed     Abstract available


    October 2020
  17. GUERINI-ROCCO E, Gray KP, Fumagalli C, Reforgiato MR, et al
    Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-0126.
    PubMed     Abstract available


    September 2020
  18. BARDIA A, Modi S, Oliveira M, Cortes J, et al
    Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
    Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-1068.
    PubMed     Abstract available


  19. ISHAK CA, De Carvalho DD
    DNA methylation profiling of premalignant lesions as a path to ovarian cancer early detection.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-3331.
    PubMed     Abstract available


  20. YANG H, Mao W, Rodriguez-Aguayo C, Mangala LS, et al
    Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
    Clin Cancer Res. 2020;26:5050.
    PubMed    


  21. JIN ZH, Tsuji AB, Degardin M, Sugyo A, et al
    Radiotheranostic Agent (64)Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer.
    Clin Cancer Res. 2020 Sep 15. pii: 1078-0432.CCR-20-1205.
    PubMed     Abstract available


  22. JORDAN K, Sikora MJ, Slansky JE, Minic A, et al
    The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1762.
    PubMed     Abstract available


    August 2020
  23. DA SILVA DM, Enserro DM, Mayadev J, Skeate JG, et al
    Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929).
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-0776.
    PubMed     Abstract available


  24. PISANIC TR, Wang Y, Sun H, Considine M, et al
    The methylomic landscape of fallopian tube lesions associated with ovarian high-grade serous carcinoma.
    Clin Cancer Res. 2020 Aug 17. pii: 1078-0432.CCR-20-0270.
    PubMed     Abstract available


  25. MCMULLEN M, Karakasis K, Oza AM
    Moving Beyond BRCA - Incorporating Molecular Assays into Ovarian Cancer trials.
    Clin Cancer Res. 2020 Aug 14. pii: 1078-0432.CCR-20-2429.
    PubMed     Abstract available


    July 2020
  26. KRAMER P, Talhouk A, Brett MA, Chiu DS, et al
    Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
    Clin Cancer Res. 2020 Jul 31. pii: 1078-0432.CCR-20-1268.
    PubMed     Abstract available


  27. MORONEY JW, Powderly J, Lieu CH, Bendell JC, et al
    Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0477.
    PubMed     Abstract available


  28. OZA AM, Estevez-Diz MDP, Grischke EM, Hall M, et al
    A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.
    Clin Cancer Res. 2020 Jul 1. pii: 1078-0432.CCR-20-0219.
    PubMed     Abstract available


    June 2020
  29. MAY T, Oza AM
    Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer.
    Clin Cancer Res. 2020 Jun 29. pii: 1078-0432.CCR-20-1376.
    PubMed     Abstract available


  30. FADER AN, Roque DM, Siegel E, Buza N, et al
    Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
    Clin Cancer Res. 2020 Jun 29. pii: 1078-0432.CCR-20-0953.
    PubMed     Abstract available


  31. TALHOUK A, George J, Wang C, Budden T, et al
    Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE).
    Clin Cancer Res. 2020 Jun 17. pii: 1078-0432.CCR-20-0103.
    PubMed     Abstract available


    May 2020
  32. LHEUREUX S, Oaknin A, Garg S, Bruce JP, et al
    EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Clin Cancer Res. 2020 May 22. pii: 1078-0432.CCR-19-4121.
    PubMed     Abstract available


  33. SENGAL AT, Patch AM, Snell CE, Smith DS, et al
    FGFR2c mesenchymal isoform expression is associated with poor prognosis and further refines risk stratification within endometrial cancer molecular subtypes.
    Clin Cancer Res. 2020 May 15. pii: 1078-0432.CCR-19-4088.
    PubMed     Abstract available


  34. JI JX, Cochrane DR, Tessier-Cloutier B, Chen SY, et al
    Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type.
    Clin Cancer Res. 2020 May 14. pii: 1078-0432.CCR-19-1905.
    PubMed     Abstract available


  35. LAMPERT EJ, Zimmer AS, Padget MR, Cimino-Mathews A, et al
    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    Clin Cancer Res. 2020 May 12. pii: 1078-0432.CCR-20-0056.
    PubMed     Abstract available


    April 2020
  36. LI J, Pan C, Boese AC, Kang J, et al
    DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-3790.
    PubMed     Abstract available


  37. HENSLEY ML, Chavan SS, Solit DB, Murali R, et al
    Genomic Landscape of Uterine Sarcomas Defined through Prospective Clinical Sequencing.
    Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-19-3959.
    PubMed     Abstract available


  38. ARORA S, Balasubramaniam S, Zhang W, Zhang L, et al
    FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
    Clin Cancer Res. 2020 Apr 15. pii: 1078-0432.CCR-19-3979.
    PubMed     Abstract available


  39. CHOI YJ, Hur SY, Kim TJ, Hong SR, et al
    A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3.
    Clin Cancer Res. 2020;26:1616-1623.
    PubMed     Abstract available


    March 2020
  40. ROTMAN J, Heeren AM, Gassama AA, Lougheed SM, et al
    Adenocarcinoma of the uterine cervix shows impaired recruitment of cDC1 and CD8+ T cells and elevated beta-Catenin activation compared to squamous cell carcinoma.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-19-3826.
    PubMed     Abstract available


  41. YOU B, Robelin P, Tod M, Louvet C, et al
    CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.
    Clin Cancer Res. 2020 Mar 24. pii: 1078-0432.CCR-20-0054.
    PubMed     Abstract available


  42. TISCHKOWITZ M, Huang S, Banerjee S, Hague J, et al
    Small Cell Carcinoma of the Ovary, Hypercalcaemic Type - genetics, new treatment targets and current management guidelines.
    Clin Cancer Res. 2020 Mar 10. pii: 1078-0432.CCR-19-3797.
    PubMed     Abstract available


    February 2020
  43. HARRIS RS, Serebrenik AA, Argyris P, Jarvis MC, et al
    The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-2786.
    PubMed     Abstract available


    January 2020
  44. DHANI NC, Hirte HW, Wang L, Burnier JV, et al
    Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).
    Clin Cancer Res. 2020 Jan 28. pii: 1078-0432.CCR-19-2576.
    PubMed     Abstract available


  45. CASEY RT, McLean MA, Challis BG, McVeigh TP, et al
    Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans.
    Clin Cancer Res. 2020;26:391-396.
    PubMed     Abstract available


  46. ALVAREZ SECORD A, Bell Burdett K, Owzar K, Tritchler D, et al
    Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218.
    Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-0226.
    PubMed     Abstract available


    December 2019
  47. LI F, Zhang Z, Cai J, Chen X, et al
    Primary preclinical and clinical Evaluation of 68Ga-DOTA-TMVP1 as a novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer.
    Clin Cancer Res. 2019 Dec 16. pii: 1078-0432.CCR-19-1845.
    PubMed     Abstract available


  48. OZA AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, et al
    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-1638.
    PubMed     Abstract available


  49. HONG DS, Concin N, Vergote I, de Bono JS, et al
    Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-2962.
    PubMed     Abstract available


  50. CROCE S, Lesluyes T, Valle C, M'Hamdi L, et al
    The NanoCind(R) signature is an independent prognosticator of recurrence and death in uterine leiomyosarcomas.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-2891.
    PubMed     Abstract available


    November 2019
  51. MADARIAGA A, Goodwin PJ, Oza AM
    Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
    Clin Cancer Res. 2019 Nov 26. pii: 1078-0432.CCR-19-3645.
    PubMed     Abstract available


    October 2019
  52. HANDLEY KF, Sood AK
    A solution to the dilution: The role for biomarkers in advanced ovarian cancer.
    Clin Cancer Res. 2019 Oct 31. pii: 1078-0432.CCR-19-3072.
    PubMed     Abstract available


  53. SOLIMAN PT, Westin SN, Iglesias DA, Fellman BM, et al
    Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study.
    Clin Cancer Res. 2019 Oct 18. pii: 1078-0432.CCR-19-0471.
    PubMed     Abstract available


  54. MCCLOSKEY CW, Cook DP, Kelly BS, Azzi F, et al
    Metformin abrogates age-associated ovarian fibrosis.
    Clin Cancer Res. 2019 Oct 9. pii: 1078-0432.CCR-19-0603.
    PubMed     Abstract available


    September 2019
  55. SHEE K, Wells JD, Ung M, Hampsch RA, et al
    A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-2213.
    PubMed     Abstract available


  56. GERBER DE, Infante JR, Gordon MS, Goldberg SB, et al
    Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-18-3965.
    PubMed     Abstract available


  57. HEITZ F, Kommoss S, Tourani R, Grandelis A, et al
    Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer.
    Clin Cancer Res. 2019 Sep 16. pii: 1078-0432.CCR-19-1741.
    PubMed     Abstract available


  58. BONILLA L, Oza AM
    Targeting TGFbeta Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?
    Clin Cancer Res. 2019;25:5432-5434.
    PubMed     Abstract available


  59. DE JONGE MM, Ritterhouse LL, de Kroon CD, Vreeswijk MPG, et al
    Germline BRCA-associated Endometrial Carcinoma is a Distinct Clinicopathologic Entity.
    Clin Cancer Res. 2019 Sep 6. pii: 1078-0432.CCR-19-0848.
    PubMed     Abstract available


  60. MAITLAND ML, O'Cearbhaill RE, Gobburu J
    Cancer Clinical Investigators Should Converge with Pharmacometricians.
    Clin Cancer Res. 2019;25:5182-5184.
    PubMed     Abstract available


    August 2019
  61. PARMAR K, Kochupurakkal BS, Lazaro JB, Wang ZC, et al
    The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP inhibition.
    Clin Cancer Res. 2019 Aug 13. pii: 1078-0432.CCR-19-0448.
    PubMed     Abstract available


  62. YANG H, Shu Z, Jiang Y, Mao W, et al
    6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
    Clin Cancer Res. 2019 Aug 7. pii: 1078-0432.CCR-18-3448.
    PubMed     Abstract available


    July 2019
  63. ISHAK CA, Lheureux S, De Carvalho DD
    DNA methylation as a robust classifier of epithelial ovarian cancer.
    Clin Cancer Res. 2019 Jul 23. pii: 1078-0432.CCR-19-1797.
    PubMed     Abstract available


  64. YEUNG TL, Leung CS, Yip KP, Sheng J, et al
    Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer.
    Clin Cancer Res. 2019 Jul 22. pii: 1078-0432.CCR-19-0187.
    PubMed     Abstract available


  65. TINKER AV, Hirte HW, Provencher DM, Butler MO, et al
    Dose-ranging and cohort-expansion study of monalizumab(IPH2201) in advanced gynecologic malignancies:A trial of the Canadian Cancer Trials Group (CCTG):IND221.
    Clin Cancer Res. 2019 Jul 15. pii: 1078-0432.CCR-19-0298.
    PubMed     Abstract available


  66. LI Z, Zhou W, Zhang Y, Sun W, et al
    ERK regulates HIF-1alpha-mediated platinum resistance by directly targeting PHD2 in ovarian cancer.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-18-4145.
    PubMed     Abstract available


    May 2019
  67. BODELON C, Killian JK, Sampson JN, Anderson WF, et al
    Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity.
    Clin Cancer Res. 2019 May 29. pii: 1078-0432.CCR-18-3720.
    PubMed     Abstract available


  68. BEAVER JA, Coleman RL, Arend RC, Armstrong DK, et al
    Advancing Drug Development in Gynecologic Malignancies.
    Clin Cancer Res. 2019 May 24. pii: 1078-0432.CCR-19-0619.
    PubMed     Abstract available


  69. HALDER J, Kamat AA, Landen CN Jr, Han LY, et al
    Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
    Clin Cancer Res. 2019;25:3194.
    PubMed    


  70. FUCIKOVA J, Rakova J, Hensler M, Kasikova L, et al
    TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer.
    Clin Cancer Res. 2019 May 10. pii: 1078-0432.CCR-18-4175.
    PubMed     Abstract available


  71. TAO JJ, Cangemi NA, Makker V, Cadoo K, et al
    First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
    Clin Cancer Res. 2019 May 8. pii: 1078-0432.CCR-19-1065.
    PubMed     Abstract available


    April 2019
  72. XING D, Zheng G, Pallavajjala A, Schoolmeester JK, et al
    Lineage-specific alterations in gynecologic neoplasms with choriocarcinomatous differentiation: implications for origin and therapeutics.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-4278.
    PubMed     Abstract available


  73. POSTOVIT LM, Dieters-Castator DZ, Rambau PF, Kelemen LE, et al
    Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3818.
    PubMed     Abstract available


  74. KAWAKAMI E, Tabata J, Yanaihara N, Ishikawa T, et al
    Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
    Clin Cancer Res. 2019 Apr 11. pii: 1078-0432.CCR-18-3378.
    PubMed     Abstract available


  75. TAKENAKA M, Kobel M, Garsed DW, Fereday S, et al
    Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma is Not Associated with Pathological Misclassification of Tumor Histotype.
    Clin Cancer Res. 2019 Apr 9. pii: 1078-0432.CCR-18-3691.
    PubMed     Abstract available


  76. COLOMBAN O, Tod M, Leary A, Ray-Coquard I, et al
    Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
    Clin Cancer Res. 2019 Apr 1. pii: 1078-0432.CCR-18-3335.
    PubMed     Abstract available


    March 2019
  77. BYKOV Y, Zamarin D
    Virus, Vessel, Victory: A Novel Approach to Tumor Killing.
    Clin Cancer Res. 2019;25:1446-1448.
    PubMed     Abstract available


    January 2019
  78. MULLEN MM, Mutch DG
    Endometrial tumor immune response: predictive biomarker of response to immunotherapy.
    Clin Cancer Res. 2019 Jan 28. pii: 1078-0432.CCR-18-4122.
    PubMed     Abstract available


  79. GREENWOOD HE, McCormick PN, Gendron T, Glaser M, et al
    Measurement of tumor antioxidant capacity and prediction of chemotherapy resistance in preclinical models of ovarian cancer by positron emission tomography.
    Clin Cancer Res. 2019 Jan 16. pii: 1078-0432.CCR-18-3423.
    PubMed     Abstract available


  80. BINZER-PANCHAL A, Hardell E, Viklund B, Ghaderi M, et al
    Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2792.
    PubMed     Abstract available


  81. SANTEGOETS SJ, van Ham VJ, Ehsan I, Charoentong P, et al
    The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival.
    Clin Cancer Res. 2019;25:240-252.
    PubMed     Abstract available


    December 2018
  82. BLAGDEN SP, Hamilton AL, Mileshkin L, Wong S, et al
    Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-2277.
    PubMed     Abstract available


  83. KITSON S, Maskell Z, Sivalingam VN, Allen JL, et al
    PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a multi-center, randomized double-blind, placebo-controlled phase 3 trial.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-3339.
    PubMed     Abstract available


  84. TALHOUK A, Derocher H, Schmidt P, Leung S, et al
    Molecular subtype not immune response drives outcomes in endometrial carcinoma.
    Clin Cancer Res. 2018 Dec 6. pii: 1078-0432.CCR-18-3241.
    PubMed     Abstract available


    November 2018
  85. HOLST F, Werner HMJ, Mjos S, Hoivik EA, et al
    PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
    Clin Cancer Res. 2018 Nov 15. pii: 1078-0432.CCR-18-0452.
    PubMed     Abstract available


  86. DE JONGE MM, Auguste A, van Wijk LM, Schouten PC, et al
    Frequent homologous recombination deficiency in high-grade endometrial carcinomas.
    Clin Cancer Res. 2018 Nov 9. pii: 1078-0432.CCR-18-1443.
    PubMed     Abstract available


    October 2018
  87. WU G, Cao L, Zhu J, Tan Z, et al
    Loss of RBMS3 Confers Platinum-resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2554.
    PubMed     Abstract available


    September 2018
  88. MATUSZEWSKA K, Santry LA, Van Vloten JP, Au Yeung A, et al
    Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in Advanced Stage Ovarian Cancer.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-0220.
    PubMed     Abstract available


    August 2018
  89. LHEUREUX S, Tinker AV, Clarke BA, Ghatage P, et al
    A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1244.
    PubMed     Abstract available


  90. PISANIC TR, Cope L, Lin SF, Yen TT, et al
    Methylomic analysis of ovarian cancers identifies tumor-specific alterations readily detectable in early precursor lesions.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1199.
    PubMed     Abstract available


  91. SOUMERAI TE, Donoghue MTA, Bandlamudi C, Srinivasan P, et al
    CLINICAL UTILITY OF PROSPECTIVE MOLECULAR CHARACTERIZATION IN ADVANCED ENDOMETRIAL CANCER.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0412.
    PubMed     Abstract available


    July 2018
  92. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    PubMed     Abstract available


  93. MCNEISH IA
    Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack?
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1731.
    PubMed     Abstract available


  94. CHEN GM, Kannan L, Geistlinger L, Kofia V, et al
    Consensus on Molecular Subtypes of High-grade Serous Ovarian Carcinoma.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0784.
    PubMed     Abstract available


  95. BLYUSS O, Burnell M, Ryan A, Gentry-Maharaj A, et al
    Comparison of longitudinal CA125 algorithms as a first line screen for ovarian cancer in the general population.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0208.
    PubMed     Abstract available


  96. YANG H, Mao W, Rodriguez-Aguayo C, Mangala LS, et al
    Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0504.
    PubMed     Abstract available


    June 2018
  97. SIMPKINS F, Jang K, Yoon H, Hew K, et al
    Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells.
    Clin Cancer Res. 2018 Jun 29. pii: 1078-0432.CCR-17-3697.
    PubMed     Abstract available


  98. LEE J, Chang CL, Lin JB, Wu MH, et al
    Skeletal Muscle Loss is an Imaging Biomarker of Outcome After Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Clin Cancer Res. 2018 Jun 29. pii: 1078-0432.CCR-18-0788.
    PubMed     Abstract available


  99. BONAZZOLI E, Predolini F, Cocco E, Bellone S, et al
    Inhibition of BET bromodomain proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a biologically aggressive variant of Endometrial Cancer.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-18-0864.
    PubMed     Abstract available


  100. KONSTANTINOPOULOS PA, Matulonis UA
    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-18-1314.
    PubMed     Abstract available


  101. TUMIATI M, Hietanen S, Hynninen J, Pietila E, et al
    A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-17-3770.
    PubMed     Abstract available


    May 2018
  102. DENIGER DC, Pasetto A, Robbins PF, Gartner JJ, et al
    T-cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers.
    Clin Cancer Res. 2018 May 31. pii: 1078-0432.CCR-18-0573.
    PubMed     Abstract available


  103. GRISHAM R, Moore KN, Gordon MS, Harb W, et al
    Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0494.
    PubMed     Abstract available


  104. UUSI-KERTTULA H, Davies JA, Thompson J, Wongthida P, et al
    Ad5NULL-A20 - a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-1089.
    PubMed     Abstract available


  105. SASANO T, Mabuchi S, Kozasa K, Kuroda H, et al
    The highly metastatic nature of uterine cervical/endometrial cancer displaying tumor-related leukocytosis: clinical and preclinical investigations.
    Clin Cancer Res. 2018 May 11. pii: 1078-0432.CCR-17-2472.
    PubMed     Abstract available


  106. MATSUDA T, Leisegang M, Park JH, Ren L, et al
    Induction of Neoantigen-specific Cytotoxic T Cells and Construction of T-cell Receptor-engineered T cells for Ovarian Cancer.
    Clin Cancer Res. 2018 May 2. pii: 1078-0432.CCR-18-0142.
    PubMed     Abstract available


    April 2018
  107. CAUMANNS JJ, Berns K, Wisman GBA, Fehrmann RSN, et al
    Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3060.
    PubMed     Abstract available


  108. DI LJ, Hao D, Liu J, Chen M, et al
    Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemo-sensitivity.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-3862.
    PubMed     Abstract available


  109. BELUR NAGARAJ A, Kovalenko O, Avelar RA, Joseph P, et al
    Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer.
    Clin Cancer Res. 2018 Apr 13. pii: 1078-0432.CCR-17-2885.
    PubMed     Abstract available


  110. ISON G, Howie LJ, Amiri-Kordestani L, Zhang L, et al
    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-18-0042.
    PubMed     Abstract available


  111. PULLIAM N, Fang F, Ozes AR, Tang J, et al
    An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0204.
    PubMed     Abstract available


    March 2018
  112. ZHU H, Gu X, Xia L, Zhou Y, et al
    A Novel TGF-beta Trap Blocks Chemotherapeutics-Induced TGF-beta1 Signaling and Enhances Their Anticancer Activity in Gynecological Cancers.
    Clin Cancer Res. 2018 Mar 16. pii: 1078-0432.CCR-17-3112.
    PubMed     Abstract available


  113. KALLI KR, Block MS, Kasi PM, Erskine CL, et al
    Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients.
    Clin Cancer Res. 2018 Mar 15. pii: 1078-0432.CCR-17-2499.
    PubMed     Abstract available


  114. MATEI D, Ghamande S, Roman LD, Alvarez Secord A, et al
    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3055.
    PubMed     Abstract available


    February 2018
  115. HUANG YF, Wu YH, Cheng WF, Peng SL, et al
    Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-2943.
    PubMed     Abstract available


  116. LANG JD, Hendricks WPD, Orlando KA, Yin H, et al
    Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition.
    Clin Cancer Res. 2018 Feb 9. pii: 1078-0432.CCR-17-1928.
    PubMed     Abstract available


  117. SHAH A, Bloomquist E, Tang S, Fu W, et al
    FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-2369.
    PubMed     Abstract available


    January 2018
  118. BELLONE S, Buza N, Choi J, Zammataro L, et al
    Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-1805.
    PubMed     Abstract available


  119. HARDWICK NR, Frankel P, Ruel C, Kilpatrick J, et al
    p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2709.
    PubMed     Abstract available


    December 2017
  120. TUCKER DW, Getchell CR, McCarthy ET, Ohman AW, et al
    Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1958.
    PubMed     Abstract available


    November 2017
  121. NORQUIST BM, Brady MF, Harrell MI, Walsh T, et al
    Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-1327.
    PubMed     Abstract available


  122. PENG G, Mills GB
    Surviving ovarian cancer: an affair between defective DNA repair and RB1.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-3022.
    PubMed     Abstract available


    October 2017
  123. LABIDI-GALY SI, Olivier T, Rodrigues M, Ferraioli D, et al
    Location of mutation in BRCA2 gene and survival in patients with ovarian cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.2136.2017.
    PubMed     Abstract available


  124. BANERJI U, Dean E, Perez-Fidalgo JA, Batist G, et al
    A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers.
    Clin Cancer Res. 2017 Oct 24. pii: clincanres.2260.2017.
    PubMed     Abstract available


  125. GARSED DW, Alsop K, Fereday S, Emmanuel C, et al
    Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1621.2017.
    PubMed     Abstract available


  126. KREUZINGER C, Geroldinger A, Smeets D, Braicu EI, et al
    A complex network of tumor microenvironment in human high grade serous ovarian cancer.
    Clin Cancer Res. 2017 Oct 2. pii: clincanres.1159.2017.
    PubMed     Abstract available


    September 2017
  127. COOKE SL, Ennis D, Evers L, Dowson S, et al
    The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.1789.2017.
    PubMed     Abstract available


  128. HAO D, Li J, Jia S, Meng Y, et al
    Integrated analysis reveals tubal and ovarian originated serous ovarian cancer and predicts differential therapeutic responses.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0638.2017.
    PubMed     Abstract available


  129. DEPREEUW J, Stelloo E, Osse EM, Creutzberg CL, et al
    Amplification of 1q32.1 refines the molecular classification of endometrial carcinoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0566.2017.
    PubMed     Abstract available


  130. TRABOULSI W, Sergent F, Boufettal H, Brouillet S, et al
    Antagonism of EG-VEGF receptors as targeted therapy for choriocarcinoma progression in vitro and in vivo.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0811.2017.
    PubMed     Abstract available


  131. KANG Z, Stevanovic S, Hinrichs CS, Cao L, et al
    Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping and Monitoring.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.1553.2017.
    PubMed     Abstract available


    March 2017
  132. LEE JM, Peer CJ, Yu M, Amable L, et al
    Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Clin Cancer Res. 2017;23:1397-1406.
    PubMed     Abstract available


  133. APELLANIZ-RUIZ M, Tejero H, Inglada-Perez L, Sanchez-Barroso L, et al
    Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
    Clin Cancer Res. 2017;23:1227-1235.
    PubMed     Abstract available


    April 2016
  134. TIPER IV, Temkin SM, Spiegel S, Goldblum SE, et al
    VEGF potentiates GD3-mediated immune suppression by human ovarian cancer cells.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2518.2015.
    PubMed     Abstract available


  135. TERRY KL, Schock H, Fortner RT, Husing A, et al
    A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort.
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.0316.2016.
    PubMed     Abstract available


    March 2016
  136. FJELDBO CS, Julin CH, Lando M, Forsberg MF, et al
    Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.
    Clin Cancer Res. 2016 Mar 24. pii: clincanres.2322.2015.
    PubMed     Abstract available


  137. DAS BC, Tyagi A, Vishnoi K, Mahata S, et al
    Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self renewal through upregulation of HES1.
    Clin Cancer Res. 2016 Mar 17. pii: clincanres.2574.2015.
    PubMed     Abstract available


    January 2016
  138. BONITO NA, Borely J, Wilhelm-Benartzi C, Ghaem-Maghami S, et al
    Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.1669.2015.
    PubMed     Abstract available


  139. KROEGER DR, Milne K, Nelson BH
    Tumor infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T cell responses, and superior prognosis in ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2762.2015.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: